Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants.

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 19, 2024

Primary Completion Date

September 9, 2024

Study Completion Date

September 9, 2024

Conditions

Healthy Volunteer

Interventions

COMBINATION_PRODUCT

budesonide/albuterol sulfate metered dose inhaleor (BDA MDI)

BDA MDI 160 μg/180 μg (single dose administered as 2 actuations of 80 μg/90 μg)

Trial Locations (1)

Research Site, Shanghai